Yu-Ting Kuo

Yu-Ting Kuo

Auto-generated profile, based on publicly available information

Yu-Ting Kuo

Division of Endoscopy, Department of Integrated Diagnostics & Therapeutics, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YIYuhei Iwasa
Yuhei Iwasa
TITakuji Iwashita
Takuji Iwashita
YTYuji Takeuchi
Yuji Takeuchi
HIHironao Ichikawa
Hironao Ichikawa
NMNaoki Mita
Naoki Mita
THTakeshi Hara
Takeshi Hara
Background: Contrast-enhanced endoscopic ultrasound (CE-EUS) is useful for the differentiation of pancreatic tumors. Using deep learning for the segmentation and classification of pancreatic tumors might further improve the diagnostic capability of CE-EUS. Aims: The aim of this study was to evaluate the capability of deep learning for the automatic segmentation of pancreatic tumors on CE-EUS video images and possible factors affecting the automatic segmentation. Methods: This retrospective study included 100 patients who underwent CE-EUS for pancreatic tumors. The CE-EUS video images were converted from the originals to 90-s segments with six frames per second. Manual segmentation of pancreatic tumors from B-mode images was performed as ground truth. Automatic segmentation was performed using U-Net with 100 epochs and was evaluated with 4-fold cross-validation. The degree of respiratory movement (RM) and tumor boundary (TB) were divided into 3-degree intervals in each patient and evaluated as possible factors affecting the segmentation. The concordance rate was calculated using the intersection over union (IoU). Results: The median IoU of all cases was 0.77. The median IoUs in TB-1 (clear around), TB-2, and TB-3 (unclear more than half) were 0.80, 0.76, and 0.69, respectively. The IoU for TB-1 was significantly higher than that of TB-3 (p < 0.01). However, there was no significant difference between the degrees of RM. Conclusions: Automatic segmentation of pancreatic tumors using U-Net on CE-EUS video images showed a decent concordance rate. The concordance rate was lowered by an unclear TB but was not affected by RM.

2 October 2018 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
FCfor the Taiwan Gastrointestinal Disease and Helicobacter Consortium
for the Taiwan Gastrointestinal Disease and Helicobacter Consortium
JLJyh-Ming Liou
Jyh-Ming Liou
PCPo Yueh Chen
Po Yueh Chen
YKYu-Ting Kuo
Yu-Ting Kuo
MWMing-Shiang Wu
Ming-Shiang Wu
In the face of rising prevalence of antibiotic resistance, susceptibility testing to provide personalized treatment is recommended prior to eradication therapy for Helicobacter pylori (H. pylori). Yet, population specific treatment according to the local prevalence of antibiotic resistance may be an alternative if susceptibility testing is not available. In this article, we reviewed the global prevalence of primary antibiotic resistance and the efficacies of commonly used regimens in antibiotic susceptible and resistance strains. We then constructed a model to predict the efficacies of these regimens and proposed an algorithm to choose the optimal first-line and rescue therapies according to the prevalence of antibiotic resistance. Clarithromycin-based therapy (triple, sequential, concomitant, and hybrid therapies) for 14 days remains the treatment of choice in regions with low clarithromycin resistance (≤15%) and bismuth quadruple therapy may be an alternative therapy. In regions with high clarithromycin resistance (> 15%), bismuth quadruple therapy is the treatment of choice and non-bismuth quadruple therapy may be an alternative. Either levofloxacin-based therapy or bismuth quadruple therapy may be used as second-line rescue therapy for patients fail after clarithromycin-based therapies, whereas levofloxacin-based therapy may be used for patients fail after bismuth quadruple therapy. Susceptibility testing or genotypic resistance should be determined after two or more eradication failures. However, empirical therapy according to prior medication history to avoid the empirical reuse of levofloxacin and clarithromycin may be an acceptable alternative after consideration of cost, patient preference, and accessibility. Rifabutin-based therapy for 14 days may serve as the fourth-line therapy. New antibiotics specific for H. pylori are highly anticipated.

3 March 2024 in Digestive Endoscopy
Verified
Journal Article
Open access
CCCharing Ching-Ning Chong
Charing Ching-Ning Chong
RPRapat Pittayanon
Rapat Pittayanon
NPNonthalee Pausawasdi
Nonthalee Pausawasdi
VBVikram Bhatia
Vikram Bhatia
NONozomi Okuno
Nozomi Okuno
MKMitsuhiro Kida
Mitsuhiro Kida
Objectives: This consensus was developed by the Asian EUS Group (AEG), who aimed to formulate a set of practice guidelines addressing various aspects of endoscopic ultrasound‐guided tissue acquisition (EUS‐TA).Methods: The AEG initiated the development of consensus statements and formed an expert panel comprising surgeons, gastroenterologists, and pathologists. Three online consensus meetings were conducted to consolidate the statements and votes. The statements were presented and discussed in the first two consensus meetings and revised according to comments. Final voting was conducted at a third consensus meeting. The Grading of Recommendations, Assessment, Development, and Evaluation system was adopted to define the strength of the recommendations and quality of evidence.Results: A total of 20 clinical questions and statements regarding EUS‐TA were formulated. The committee recommended that fine‐needle biopsy (FNB) needles be preferred over conventional fine‐needle aspiration (FNA) needles for EUS‐TA of subepithelial lesions. For solid pancreatic masses, rapid on‐site evaluation is not routinely recommended when FNB needles are used. For dedicated FNB needles, fork‐tip and Franseen‐tip needles have essentially equivalent performance.Conclusion: This consensus provides guidance for EUS‐TA, thereby enhancing the quality of EUS‐TA.

2 August 2020 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
PDF file
KCKai‐Hsiang Stanley Chen
Kai‐Hsiang Stanley Chen
LKLi-Ta Keng
Li-Ta Keng
YKYu‐Ting Kuo
Yu‐Ting Kuo
Yi-Cheng TaiYi-Cheng Tai
Yi-Cheng Tai
RCRobert Chen
Robert Chen
Click on the article title to read more.

1 November 2019 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
PYPo-Jen Yang
Po-Jen Yang
YKYu-Ting Kuo
Yu-Ting Kuo
CCChien-Chuan Chen
Chien-Chuan Chen
Hsiu-Po WangHsiu-Po Wang
Hsiu-Po Wang

4 September 2023 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
WWWeng-Fai Wong
Weng-Fai Wong
YKYu-Ting Kuo
Yu-Ting Kuo
MHMing-Lun Han
Ming-Lun Han
Hsiu-Po WangHsiu-Po Wang
Hsiu-Po Wang
A prediction system for common bile duct (CBD) stones was originally published by the American Society for Gastrointestinal Endoscopy (ASGE) in 2010 and was last revised in 2019. We wanted to investigate its application in an Asian population, who have different etiologies of bile duct stone formation and accessibility to medical service compared to the West. This is a single center retrospective study. Patients who received endoscopic ultrasound (EUS) for suspected CBD stones were collected from our endoscopic record system over a 10-year period. The accuracy of the revised ASGE criteria was estimated according to the results of EUS. A minimum follow-up of 6 months was required to detect false negative results. 142 patients were enrolled, 87 (61%) patients had CBD stones. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the revised ASGE criteria for high-risk patients were 69%, 38%, 64%, 44%, and 57%. 36% of the ASGE-defined high-risk patients negative for CBD stones on EUS. The two significant predictors for CBD stone were CBD dilatation (adjusted OR 3.06, 95% C.I. 1.31-7.17, p = 0.010) and ascending cholangitis (adjusted OR 2.28, 95% C.I. 1.01-5.15, p = 0.047). ASGE recommends that patients defined as high-risk for choledocholithiasis be considered for direct ERCP without prior need for confirmation imaging. However, our findings indicate a high rate (36%) of patients in that group negative for CBD stones on EUS. Hence, EUS is still be suggested first in selective high-risk patients so that diagnostic ERCP can be avoided in our Asian society.